COVID-19患者和未接触者中针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的T细胞反应
SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals.
作者信息
Rha Min-Seok, Kim A Reum, Shin Eui-Cheol
机构信息
Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea.
The Center for Epidemic Preparedness, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea.
出版信息
Immune Netw. 2021 Feb 17;21(1):e2. doi: 10.4110/in.2021.21.e2. eCollection 2021 Feb.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus disease 2019 (COVID-19), an ongoing pandemic disease. In the current review, we describe SARS-CoV-2-specific CD4 and CD8 T-cell responses in acute and convalescent COVID-19 patients. We also discuss the relationships between COVID-19 severity and SARS-CoV-2-specific T-cell responses and summarize recent reports regarding SARS-CoV-2-reactive T cells in SARS-CoV-2-unexposed individuals. These T cells may be cross-reactive cells primed by previous infection with human common-cold coronaviruses. Finally, we outline SARS-CoV-2-specific T-cell responses in the context of vaccination. A better understanding of SARS-CoV-2-specific T-cell responses is needed to develop effective vaccines and therapeutics.
摘要
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染会引发2019冠状病毒病（COVID-19），这是一种仍在流行的疾病。在当前的综述中，我们描述了急性和康复期COVID-19患者中针对SARS-CoV-2的CD4和CD8 T细胞反应。我们还讨论了COVID-19严重程度与针对SARS-CoV-2的T细胞反应之间的关系，并总结了关于未接触过SARS-CoV-2的个体中SARS-CoV-2反应性T细胞的最新报告。这些T细胞可能是由先前感染人类普通感冒冠状病毒而引发的交叉反应性细胞。最后，我们概述了在疫苗接种背景下针对SARS-CoV-2的T细胞反应。为了开发有效的疫苗和治疗方法，需要更好地了解针对SARS-CoV-2的T细胞反应。
相似文献
1
SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals.COVID-19患者和未接触者中针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的T细胞反应
Immune Netw. 2021 Feb 17;21(1):e2. doi: 10.4110/in.2021.21.e2. eCollection 2021 Feb.
2
HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients.补体缺陷患者中存在与 HCoV 和 SARS-CoV-2 发生交叉反应的 T 细胞。
Front Immunol. 2020 Dec 23;11:607918. doi: 10.3389/fimmu.2020.607918. eCollection 2020.
3
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.SARS-CoV-2 反应性 T 细胞在健康供体和 COVID-19 患者中的研究。
Nature. 2020 Nov;587(7833):270-274. doi: 10.1038/s41586-020-2598-9. Epub 2020 Jul 29.
4
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.COVID-19 和 SARS 病例以及未感染对照者的 SARS-CoV-2 特异性 T 细胞免疫。
Nature. 2020 Aug;584(7821):457-462. doi: 10.1038/s41586-020-2550-z. Epub 2020 Jul 15.
5
Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4 T-cell response with pre-primed responses directed against common cold coronaviruses.针对 SARS-CoV-2 NSP12 定向 CD4 T 细胞反应与针对普通感冒冠状病毒的预先存在反应的广泛交叉反应性的证据。
Front Immunol. 2023 May 5;14:1182504. doi: 10.3389/fimmu.2023.1182504. eCollection 2023.
6
Vaccinated and Convalescent Donor-Derived Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells as Adoptive Immunotherapy for High-Risk Coronavirus Disease 2019 Patients.接种疫苗和康复期供体来源的严重急性呼吸综合征冠状病毒 2 特异性 T 细胞作为适应性免疫疗法用于高危新型冠状病毒病 2019 患者。
Clin Infect Dis. 2021 Dec 6;73(11):2073-2082. doi: 10.1093/cid/ciab371.
7
Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity.不同疾病严重程度的新冠肺炎患者CD4 T细胞和抗体反应的动态变化
Front Med (Lausanne). 2020 Nov 11;7:592629. doi: 10.3389/fmed.2020.592629. eCollection 2020.
8
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.微针阵列递呈的重组冠状病毒疫苗：免疫原性和快速转化开发。
EBioMedicine. 2020 May;55:102743. doi: 10.1016/j.ebiom.2020.102743. Epub 2020 Apr 2.
9
Dynamic SARS-CoV-2-Specific Immunity in Critically Ill Patients With Hypertension.急危重症高血压患者的 SARS-CoV-2 特异性动态免疫。
Front Immunol. 2020 Dec 10;11:596684. doi: 10.3389/fimmu.2020.596684. eCollection 2020.
10
Understanding the Host Innate Immune Responses against SARS-CoV-2 Infection and COVID-19 Pathogenesis.了解宿主针对新型冠状病毒感染和新冠肺炎发病机制的固有免疫反应。
Immune Netw. 2021 Feb 26;21(1):e1. doi: 10.4110/in.2021.21.e1. eCollection 2021 Feb.
引用本文的文献
1
Mucosal Vaccination Against SARS-CoV-2 Using Human Probiotic Spores as an Adjuvant Induces Potent Systemic and Mucosal Immunity.使用人类益生菌孢子作为佐剂的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的黏膜疫苗可诱导强大的全身和黏膜免疫。
Vaccines (Basel). 2025 Jul 21;13(7):772. doi: 10.3390/vaccines13070772.
2
Long term outcomes after COVID-19 in patients with schizophrenia: a historical cohort study in a health maintenance organization.精神分裂症患者感染新冠病毒后的长期结局：一项健康维护组织中的历史性队列研究
Soc Psychiatry Psychiatr Epidemiol. 2025 Aug;60(8):2013-2022. doi: 10.1007/s00127-025-02860-0. Epub 2025 Mar 3.
3
Mucosal Immunity against SARS-CoV-2 in the Respiratory Tract.呼吸道中针对严重急性呼吸综合征冠状病毒2的黏膜免疫
Pathogens. 2024 Jan 26;13(2):113. doi: 10.3390/pathogens13020113.
4
Integrative single-cell analysis: dissecting CD8 + memory cell roles in LUAD and COVID-19 via eQTLs and Mendelian Randomization.整合单细胞分析：通过 eQTL 和孟德尔随机化解析 LUAD 和 COVID-19 中 CD8+记忆细胞的作用。
Hereditas. 2024 Jan 31;161(1):7. doi: 10.1186/s41065-023-00307-7.
5
SARS-CoV-2 mRNA Vaccine Elicits Sustained T Cell Responses Against the Omicron Variant in Adolescents.严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗在青少年中引发针对奥密克戎变异株的持续T细胞反应。
Immune Netw. 2023 Aug 11;23(4):e33. doi: 10.4110/in.2023.23.e33. eCollection 2023 Aug.
6
Potential use of endemic human coronaviruses to stimulate immunity against pathogenic SARS-CoV-2 and its variants.内源性人冠状病毒的潜在用途，以刺激对致病的 SARS-CoV-2 及其变体的免疫。
Libyan J Med. 2023 Dec;18(1):2209949. doi: 10.1080/19932820.2023.2209949.
7
Corticosteroids reduce pathologic interferon responses by downregulating STAT1 in patients with high-risk COVID-19.皮质类固醇通过下调高危 COVID-19 患者中的 STAT1 来减少病理性干扰素反应。
Exp Mol Med. 2023 Mar;55(3):653-664. doi: 10.1038/s12276-023-00964-8. Epub 2023 Mar 20.
8
Human CD8 T-Cell Populations That Express Natural Killer Receptors.表达自然杀伤受体的人类CD8 T细胞群体。
Immune Netw. 2023 Feb 20;23(1):e8. doi: 10.4110/in.2023.23.e8. eCollection 2023 Feb.
9
Monocytic-Myeloid Derived Suppressor Cells Suppress T-Cell Responses in Recovered SARS CoV2-Infected Individuals.单核细胞/髓样来源的抑制细胞抑制恢复期 SARS-CoV2 感染个体的 T 细胞反应。
Front Immunol. 2022 Jun 24;13:894543. doi: 10.3389/fimmu.2022.894543. eCollection 2022.
10
Long-Term Elevated Inflammatory Protein Levels in Asymptomatic SARS-CoV-2 Infected Individuals.无症状 SARS-CoV-2 感染者长期炎症蛋白水平升高。
Front Immunol. 2021 Sep 17;12:709759. doi: 10.3389/fimmu.2021.709759. eCollection 2021.
本文引用的文献
1
Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study.比较 COVID-19 和季节性流感的特征、发病率和死亡率：一项全国性、基于人群的回顾性队列研究。
Lancet Respir Med. 2021 Mar;9(3):251-259. doi: 10.1016/S2213-2600(20)30527-0. Epub 2020 Dec 17.
2
PD-1-Expressing SARS-CoV-2-Specific CD8 T Cells Are Not Exhausted, but Functional in Patients with COVID-19.PD-1 表达的 SARS-CoV-2 特异性 CD8 T 细胞并未衰竭，而是在 COVID-19 患者中具有功能。
Immunity. 2021 Jan 12;54(1):44-52.e3. doi: 10.1016/j.immuni.2020.12.002. Epub 2020 Dec 14.
3
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.在一项 1/2 期临床试验中，单次接种 ChAdOx1 nCoV-19（AZD1222）疫苗诱导的 T 细胞和抗体反应。
Nat Med. 2021 Feb;27(2):270-278. doi: 10.1038/s41591-020-01194-5. Epub 2020 Dec 17.
4
SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors.SARS-CoV-2 表位被广泛的人类 T 细胞受体识别。
Immunity. 2020 Dec 15;53(6):1245-1257.e5. doi: 10.1016/j.immuni.2020.11.004. Epub 2020 Nov 13.
5
Correlates of protection against SARS-CoV-2 in rhesus macaques.恒河猴中 SARS-CoV-2 保护作用的相关因素。
Nature. 2021 Feb;590(7847):630-634. doi: 10.1038/s41586-020-03041-6. Epub 2020 Dec 4.
6
Characterization of pre-existing and induced SARS-CoV-2-specific CD8 T cells.鉴定存在的和诱导的 SARS-CoV-2 特异性 CD8 T 细胞。
Nat Med. 2021 Jan;27(1):78-85. doi: 10.1038/s41591-020-01143-2. Epub 2020 Nov 12.
7
Unbiased Screens Show CD8 T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein.非偏向性筛选表明 COVID-19 患者的 CD8 T 细胞识别 SARS-CoV-2 中的共享表位，这些表位主要位于 Spike 蛋白之外。
Immunity. 2020 Nov 17;53(5):1095-1107.e3. doi: 10.1016/j.immuni.2020.10.006. Epub 2020 Oct 20.
8
Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4 T Cells in COVID-19.COVID-19 中 SARS-CoV-2 反应性调节性和细胞毒性 CD4 T 细胞的失衡。
Cell. 2020 Nov 25;183(5):1340-1353.e16. doi: 10.1016/j.cell.2020.10.001. Epub 2020 Oct 5.
9
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.急性 COVID-19 患者中针对 SARS-CoV-2 的抗原特异性适应性免疫反应，及其与年龄和疾病严重程度的关联。
Cell. 2020 Nov 12;183(4):996-1012.e19. doi: 10.1016/j.cell.2020.09.038. Epub 2020 Sep 16.
10
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition.SARS-CoV-2 衍生肽定义了异源和 COVID-19 诱导的 T 细胞识别。
Nat Immunol. 2021 Jan;22(1):74-85. doi: 10.1038/s41590-020-00808-x. Epub 2020 Sep 30.
Zotero 插件